EEF1A2 and pancreatic ductal adenocarcinoma: In a previous report, an anti-STn antigen-specific antibody was employed to modify nanogels because of the aberrant expression of Sialyl Tn (STn) antigen in pancreatic ductal adenocarcinoma (PDAC), resulting in the effective accumulation of drugs in tumor tissues, which not only improved the antitumor effect, but also implied a promising target for PDAC [71].